drugset / Trial / NCT01924533

Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

NCT01924533

Phase 3 Completed 525 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a phase III, multi-centre study of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy. Patients will be from China, Japan , Korea and Taiwan.

Timeline

Start
2013-09-03
Primary completion
2016-04-04
Completion
2023-03-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Olaparib Small molecule 300 mg Oral
Background Paclitaxel Small molecule 80 mg/m2 Intravenous

Indications